Clinical trial
A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets…
NCT00326391 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry · Completed
Key facts
| NCT number | NCT00326391 |
|---|---|
| Title | A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder |
| Official title | A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day. |
| Lead sponsor | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | methylphenidate hydrochloride extended-release tablets |
| Enrollment | 229 |
| Start date | Apr 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | May 16, 2006 |
| Last update posted | May 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: